U.S. markets open in 6 hours 38 minutes

Sysmex Corporation (0YX.F)

Frankfurt - Frankfurt Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
14.20-0.50 (-3.29%)
A partir del 08:16AM CEST. Mercado abierto.

Sysmex Corporation

1-5-1 Wakinohama-kaigandori
Chuo-ku
Kobe 651-0073
Japan
81 78 265 0500
https://www.sysmex.co.jp

Sector(es)Healthcare
IndustriaMedical Instruments & Supplies
Empleados a tiempo completo10,042

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Hisashi IetsuguChairman of the Managing Board & Group CEO1.33MN/D1949
Mr. Kaoru AsanoPresident & Representative DirectorN/DN/D1958
Mr. Chris CappellaChief Financial OfficerN/DN/DN/D
Mr. Tomokazu YoshidaManaging Executive Officer, CTO & Member of the Managing BoardN/DN/D1964
Mr. Frank BuescherSenior Executive OfficerN/DN/DN/D
Mr. Iwane MatsuiSenior Managing Executive Officer & Member of the Managing BoardN/DN/D1961
Mr. Kenji TachibanaSr. MD of Corp Mgmt & Regulatory Affairs, Sr. Exec. Officer & Member of the Managing BoardN/DN/D1957
Mr. Kensuke IizukaSenior Executive Officer & Executive VP of Corporate Business Planning Div.N/DN/DN/D
Mr. Zuo Hui PengExecutive OfficerN/DN/DN/D
Mr. Takashi OnoMember of the Managing Board, Senior Executive Officer & MDN/DN/D1965
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Gestión corporativa

La calificación ISS Governance QuickScore de Sysmex Corporation a partir del 29 de junio de 2024 es 4. Las puntuaciones principales son Auditoría: 1; Junta: 6; Derechos del accionista: 4; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.